Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells

Cancer Research

Volumn 60, Issue 7, 2000, Pages 1901-1907

  Ferraro, Carole ^a   Quemeneur, Laurence ^a   Prigent, Annie France ^b   Taverne, Catherine ^a   Revillard, Jean Pierre ^a   Bonnefoy Berard, Nathalie ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTHRACYCLINE DERIVATIVE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CAMPTOTHECIN; CASPASE 3; CERAMIDE; CYTOTOXIC AGENT; DAUNORUBICIN; DNA; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; FLUOROURACIL; GLUTATHIONE; LIPOCORTIN 5; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLSERINE; PHYTOHEMAGGLUTININ; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; DRUG CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA; LYMPH NODE; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SPLEEN; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; THYMUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CAMPTOTHECIN; CELL CYCLE; CELLS, CULTURED; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; G0 PHASE; G1 PHASE; HUMANS; LYMPH NODES; LYMPHOCYTE DEPLETION; LYMPHOCYTES; METHOTREXATE; MICE; MICE, INBRED BALB C; SPLEEN; T-LYMPHOCYTES; THYMUS GLAND;

EID: 0034028050     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Chabner, B. A., and Myers, C. E. Clinical pharmacology of cancer chemotherapy. In: V. T. J. De Vitta, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 349-395. Philadelphia: J. B. Lippincott Co., 1989.
2. Schaap, N., Schattenberg, A., Bar, B., Preijers, F., Geurts van Kessel, A., van der Maazen, R., de Boo, T., and de Witte, T. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen. Br. J. Haematol., 98: 750-759, 1997.
3. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
4. Herr, I., Wilhelm, D., Bohler, T., Angel, P., and Debatin, K. M. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J., 16: 6200-6208, 1997.
5. Jaffrezou, J. P., Levade, T., Bettaieb, A., Andrieu, N., Bezombes, C., Maestre, N., Vermeersch, S., Rousse, A., and Laurent, G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J., 15: 2417-2424, 1996.
6. Richardson, D. S., and Johnson, S. A. Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev., 11: 201-223, 1997.
7. Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K., Fuks, Z., and Kolesnick, R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell. 82: 405-411, 1995.
8. Mansat, V., Bettaieb, A., Levade, T., Laurent, G., and Jaffrezou, J. P. Serine protease inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. FASEB J., 11: 695-702, 1997.
9. Mansat, V., Laurent, G., Levade, T., Bettaieb, A., and Jaffrezou, J. P. The protein kinase C activators phorbol esters and phosphatidylserine inhibit neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. Cancer Res., 57: 5300-5304, 1997.
10. Eischen, C. M., Kottke, T. J., Martins, L. M., Basi, G. S., Tung, J. S., Earnshaw, W. C., Leibson, P. J., and Kaufmann, S. H. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood, 90: 935-943, 1997.
11. McGahon, A. J., Costa Pereira, A. P., Daly, L., and Cotter, T. G. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br. J. Haematol., 101: 539-547, 1998.
12. Tolomeo, M., Dusonchet, L., Meli, M., Grimaudo, S., D'Alessandro, N., Papoff, G., Ruberti, G., and Rausa, L. The CD95/CD95L system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ., 5: 735-742, 1998.
13. Villunger, A., Egle, A., Kos, M., Hartmann, B. L., Geley, S., Kofler, R., and Greil, R. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res., 57: 3331-3314, 1997.
14. Fournel, S., Genestier, L., Robinet, E., Flacher, M., and Revillard, J. P. Human T cells require 1L-2 but not G1/S transition to acquire susceptibility to Fas-mediated apoptosis. J. Immunol., 157: 4309-4315, 1996.
15. Fournel, S., Genestier, L., Rouault, J. P., Lizard, G., Flacher, M., Assossou, O., and Revillard, J. P. Apoptosis without decrease of cell DNA content. FEBS Lett., 367: 188-192, 1995.
16. Koopman, G., Reutelingsperger, C. P., Kuijlen, G. A., Keehnen, R. M., Pals, S. T., and van Oers, M. H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood, 84: 1415-1420. 1994.
17. Genestier, L., Prigent, A. F., Paillot, R., Quemeneur, L., Durand, I., Banchereau, J., Revillard, J. P., and Bonnefoy-Berard, N. Caspase-dependent ceramide production in Fas- and HLA class I-mediated peripheral T cell apoptosis. J. Biol. Chem., 273: 5060-5066, 1998.
18. Genestier, L., Paillot, R., Fournel, S., Ferraro, C., Miossec, P., and Revillard, J. P. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J. Clin. Investig., 102: 322-328, 1998.
19. Schreiber, S. L. Immunophilin-sensitive protein phosphatase action in cell signaling pathways. Cell, 70: 365-368, 1992.
20. Levenson, V., and Hamlin, J. L. A general protocol for evaluating the specific effects of DNA replication inhibitors. Nucleic Acids Res., 21: 3997-4004, 1993.
21. Strum, J. C., Small, G. W., Pauig, S. B., and Daniel, L. W. 1-β-D-Arabinofuranosyl-cytosine stimulates ceramide and diglyceride formation in HL-60 cells. J. Biol. Chem., 269: 15493-15497, 1994.
22. Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Investig., 99: 403-413, 1997.
23. Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J. L., Schroter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E., and Tschopp, J. Inhibition of death receptor signals by cellular FLIP. Nature (Lond.), 388: 190-195, 1997.
24. Klas, C., Debatin, K. M., Jonker, R., and Krammer, P. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol., 5: 625-630, 1993.
25. Refaeli, Y., Van Parijs, L., London, C. A., Tschopp, J., and Abbas, A. K. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity. 8: 615-623, 1998.
26. Williams, M. S., and Henkart, P. A. Role of reactive oxygen intermediates in TCR-induced death of T cell blasts and hybridomas. J. Immunol., 157: 2395-2402, 1996.
27. Morita, A., Werfel, T., Stege, H., Ahrens, C., Karmann, K., Grewe, M., Grether-Beck, S., Ruzicka, T., Kapp, A., Klotz, L. O., Sies, H., and Krutmann, J. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J. Exp. Med., 186: 1763-1768, 1997.
28. Ferraro, C., Quemeneur, L., Fournel, S., Revillard, J. P., and Bonnefoy-Berard, N. The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes. Cell Death Differ., in press, 2000.
29. Mimnaugh, E. G., Trush, M. A., and Gram, T. E. A possible role for membrane lipid peroxidation in anthracycline nephrotoxicity. Biochem. Pharmacol., 35: 4327-4135, 1986.
30. Quillet-Mary, A., Mansat, V., Duchayne, E., Come, M. G., Allouche, M., Bailly, J. D., Bordier, C., and Laurent, G. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia (Baltimore), 10: 417-425, 1996.
31. Singal, P. K., Iliskovic, N., Li, T., and Kumar, D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J., 11: 931-936, 1997.
32. Hofmann, K., and Dixit, V. M. Ceramide in apoptosis - does it really matter? Trends Biochem Sci., 23: 374-377, 1998.
33. Landowski, T. H., Gleason-Guzman, M. C., and Dalton, W. S. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood, 89: 1854-1861, 1997.
34. Hale, G., Zhang, M. J., Bunjes, D., Prentice, H. G., Spence, D., Horowitz, M. M., Barrett, A. J., and Waldmann, H. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood, 92: 4581-4590, 1998.
35. Bonnefoy-Berard, N., and Revillard, J. P. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant., 15: 435-442, 1996.
36. Enosawa, S., Suzuki, S., Kakefuda, T., Li, X. K., and Amemiya, H. Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720. Immunopharmacology, 34: 171-179, 1996.
37. Wasserman, J., Blomgren, H., Petrini, B., Baral, E., Strender, L. E., Jarstrand, C., and von Stedingk, L. V. Effect of radiation therapy and in vitro X-ray exposure on lymphocyte subpopulations and their functions. Am. J. Clin. Oncol., 5: 195-208, 1982.
38. Salam, A., and Waer, M. Graft-versus-host reactivity and graft-versus-leukemia effect in murine allogeneic bone marrow chimeras conditioned with total body irradiation or total lymphoid irradiation. Transplantation, 61: 826-830, 1996.
39. Douek, D. C., McFarland, R. D., Keiser, P. H., Gage, E. A., Massey, J. M., Haynes, B. F., Polis, M. A., Haase, A. T., Feinberg, M. B., Sullivan, J. L., Jamieson, B. D., Zack, J. A., Picker, L. J., and Koup, R. A. Changes in thymic function with age and during the treatment of HIV infection. Nature (Lond.), 396: 690-695, 1998.
40. Wang, R. F. Tumor antigens discovery: perspectives for cancer therapy. Mol. Med., 3: 716-731, 1997.
41. Yee, C., Riddell, S. R., and Greenberg, P. D. Prospects for adoptive T cell therapy. Curr. Opin. Immunol., 9: 702-708, 1997.